Essex Bio-Technology Limited (Essex or the Group, HKG: 1061) is pleased to announce that a Biologics License Application (BLA) for EB12-20145P (HLX04-O), a recombinant...
Essex Bio-Technology Ltd (Essex or the Group, HKG: 1061) today announced that a phase 1/2 clinical trial of EB12-20145P (HLX04-O), a recombinant anti-VEGF humanised...
Essex Bio-Technology Ltd. (Essex or the Group, HKG: 1061) is pleased to announce that its wholly-owned subsidiary, Majeton Pte. Ltd. (Majeton), has entered into...
Essex Bio-Technology Ltd. (Essex or the Group, HKG: 1061) is pleased to announce that its wholly-owned subsidiary, Essex Medipharma (Zhuhai) Co., Ltd. (Essex Medipharma),...
Resilience & Relevance, Growth Ready
Essex Bio-Technology Ltd (Essex or the Group, HKG: 1061) today announced the annual results for the year ended 31...
Essex Bio-Technology Ltd (Essex or the Group, HKG: 1061) today announced that two of its wholly-owned subsidiaries, Essex Bio-Investment Limited (Essex Bio-Investment) and Zhuhai...